This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Tuesday's Early Winners & Losers

Nutrition 21 (NXXI) shares were blazing, up 37% in extended trading Monday after the Purchase, N.Y., biotech's high-selenium yeast supplement, Selenomax, was shown to suppress HIV progression in a long-term University of Miami study.

The findings, published in Monday's issue of the American Medical Association's Archives of Internal Medicine journal, revealed that patients who adhered to the daily treatment regimen experienced no change in HIV-1 viral load (the proportion of viral particles present in the bloodstream) and an increase in CD4 cell count (a measure of T-helper white blood cells, which reflects overall immune-system strength).

The results remained significant even accounting for numerous test-subject traits, including whether or not the individuals also were taking antiretroviral therapy. For a time, CVS (CVS - Get Report) will exclusively carry the product, and wider availability will follow over the next few months. Nutrition 21 shares were up 70 cents to $2.59. CVS was unchanged.

Neurocrine Biosciences (NBIX - Get Report) surged after it announced it will accelerate resubmission of one version of its Indiplon insomnia treatment to the Food and Drug Administration, now expecting to do so by the second quarter. The San Diego-based company was gaining $1.31, or 10.1%, to $14.26.

Mindspeed Technologies (MSPD) was higher after its downside results for the quarter ended Dec. 31 met Wall Street estimates. The Newport Beach, Calif., maker of semiconductor-networking equipment posted a non-GAAP loss of $6.3 million, or 6 cents a share, widened from a year-ago loss of $4.2 million, or 4 cents a share. But analysts polled by Thomson Financial were expecting these numbers. Revenue sank 9% year over year to $30.2 million, also about in line with the consensus. Shares were adding 15 cents, or 8.1%, to $2.

Baltimore's Novavax (NVAX - Get Report) rose after the company said that its viruslike particle vaccines protected against two different strains of the pandemic H5N1 influenza -- or the so-called bird flu -- as shown in preclinical live-virus studies conducted with the University of Pittsburgh. The studies have been submitted for peer review, and the U.S. Centers for Disease Control and Prevention will also conduct studies to verify the data. Shares were up 35 cents, or 8.6%, to $4.44.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
MSPD $0.00 0.00%
CVS $95.46 1.50%
NVAX $8.58 0.23%
NBIX $53.24 -2.10%
SRT $3.50 0.29%


Chart of I:DJI
DOW 17,887.55 +167.63 0.95%
S&P 500 2,100.46 +20.05 0.96%
NASDAQ 5,151.7860 +43.12 0.84%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs